The Impact of the Addition of Pertuzumab to Neoadjuvant HER2 Targeting on Pathological Complete Response (pCR) Rates: Kent Oncology Centre (KOC) Experience. - Sim, V.; Forner, S.; Burcombe, R.; Glendenning, J. (Clinical Oncology, 2019)